AIBOTICS, INC.
AIBOTICS, INC. (AIBT): 6 pipeline candidates · ~25 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
24.9 months
D/E -1.18 · 0% dilution
Lead: Phase 2
6 candidates
N/A
N/A
A transparent, data-derived signal for AIBOTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$546K
Cash
$289K
Quarterly Burn
$36K
Runway
24.9 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| Milkyway | — |
| Phill Robot | — |
| Psilly | Phase 2 |
| Psilocybin (API) | Phase 2 |
| Psilocybin and related compounds | Phase 2 |
| Psilocybin SPP (API) | Phase 2 |
Frequently asked questions
How many drug candidates are in AIBOTICS, INC.'s pipeline?
AIBOTICS, INC. (AIBT) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AIBOTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AIBOTICS, INC. has approximately 24.9 months of cash runway.
What is AIBOTICS, INC.'s market capitalization?
AIBOTICS, INC.'s market capitalization is approximately $546K.
Who is the CEO of AIBOTICS, INC.?
Mr. Benjamin Kaplan is the chief executive officer of AIBOTICS, INC. (AIBT).
Get the full picture on AIBOTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.